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Abstract
Attention-deficit and hyperactivity disorder (ADHD) is a common childhood disorder with a substantial genetic
component. However, the extent to which epigenetic mechanisms play a role in the etiology of the disorder is
unknown. We performed epigenome-wide association studies (EWAS) within the Pregnancy And Childhood
Epigenetics (PACE) Consortium to identify DNA methylation sites associated with ADHD symptoms at two methylation
assessment periods: birth and school age. We examined associations of both DNA methylation in cord blood with
repeatedly assessed ADHD symptoms (age 4–15 years) in 2477 children from 5 cohorts and of DNA methylation at
school age with concurrent ADHD symptoms (age 7–11 years) in 2374 children from 9 cohorts, with 3 cohorts
participating at both timepoints. CpGs identified with nominal significance (p < 0.05) in either of the EWAS were
correlated between timepoints (ρ= 0.30), suggesting overlap in associations; however, top signals were very different.
At birth, we identified nine CpGs that predicted later ADHD symptoms (p < 1 × 10–7), including ERC2 and CREB5.
Peripheral blood DNA methylation at one of these CpGs (cg01271805 in the promoter region of ERC2, which regulates
neurotransmitter release) was previously associated with brain methylation. Another (cg25520701) lies within the gene
body of CREB5, which previously was associated with neurite outgrowth and an ADHD diagnosis. In contrast, at school
age, no CpGs were associated with ADHD with p < 1 × 10−7. In conclusion, we found evidence in this study that DNA
methylation at birth is associated with ADHD. Future studies are needed to confirm the utility of methylation variation
as biomarker and its involvement in causal pathways.
Introduction
Attention-deficit and hyperactivity disorder (ADHD) is
a common neurodevelopmental disorder characterized by
impulsivity, excessive activity, and attention problems.
Symptoms often become apparent during school age with
a world-wide prevalence of 5–7.5%1. Genetic heritability is
estimated between 64 and 88%2,3. Additionally, several
environmental factors are suspected to impact ADHD,
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e.g., prenatal maternal smoking or lead exposure4–7.
However, the genetics and environmental pathways con-
tributing to ADHD risk remain unclear. Possibly, DNA
methylation, an epigenetic mechanism regulating gene
expression, may mediate genetic or environmental effects.
Several studies have investigated DNA methylation in
relation to ADHD diagnoses or symptoms using candi-
date approaches or epigenome-wide association studies
(EWAS) in peripheral blood and saliva tissue8,9. A leading
hypothesis concerning the etiology of ADHD suggests
that deficiencies in the dopamine system of the brain
impact ADHD development4,10. Consequently, candidate
studies have focused on genes related to dopamine
function. For instance, DNA methylation alterations in
DRD411–13, DRD512, and DAT112,14 genes have been
associated with ADHD, though not consistently15. Beyond
the candidate gene approach, three studies tested DNA
methylation across the whole genome. One study per-
formed an EWAS with saliva samples in school-aged
children using a case–control design16. The study identi-
fied differentially methylated probes in VIPR2, a gene
expressed in the caudate and previously associated with
psychopathology. Another EWAS investigated cord and
peripheral blood DNA methylation at birth and at 7 years
of age17. At birth, 13 probes located in SKI, ZNF544,
ST3GAL3, and PEX2 were associated with ADHD trajec-
tories from age 7 to 15 years, but the methylation status of
these probes at age 7 was not associated with ADHD cross-
sectionally. An EWAS in adults with ADHD failed to find
any differentially methylated sites in peripheral blood18.
Large multi-center epigenome-wide studies, which allow
for increased power and generalizability, are lacking for
childhood. Here we performed the first epigenome-wide
prospective meta-analysis to identify DNA methylation
sites associated with childhood ADHD symptoms in
cohorts from the Pregnancy And Childhood Epigenetics
(PACE) Consortium19. As DNA methylation changes over
time20, so could potential associations with ADHD symp-
toms. On the one hand, one might expect that DNA
methylation levels measured around the same time as
ADHD symptoms would show the largest associations, as
these might represent the immediate effects on symptoms
or consequences of ADHD. On the other hand, causes of
ADHDmay be found early in childhood or even prenatally.
Thus methylation levels at birth may be more relevant than
later methylation profiles, as suggested by an earlier
EWAS21. Since it is unclear when DNA methylation is
most relevant for ADHD symptoms, we tested DNA
methylation both at birth using cord blood and at school
age (age 7–9 years) using DNA derived from peripheral
whole blood. In the analyses of cord blood methylation, the
aim was to explain ADHD symptoms between ages 4 and
15 years. Many participating cohorts assessed ADHD
repeatedly, and we employed a repeated-measures design
to increase precision. Furthermore, we utilized data in
childhood to examine cross-sectional DNA methylation
patterns associated with ADHD symptoms at school age.
Materials and methods
This study comprises a birth methylation EWAS and a
school-age methylation EWAS described successively below.
Birth methylation EWAS
Participants
Five cohorts (Avon Longitudinal Study of Parents and
Children (ALSPAC)22–24, Generation R (GENR)25, INfancia
y Medio Ambiente (INMA)26, Newborn Epigenetic Study
(NEST)27,28, and Prediction and prevention of preeclampsia
and intrauterine growth restriction (PREDO)29) in the
PACE consortium had information on DNA methylation in
cord blood and ADHD symptoms. These cohorts have a
combined sample size of 2477 (Table 1). Participants were
mostly of European ancestry, except for NEST, an Amer-
ican cohort that also included participants of African
ancestry. In NEST, separate EWAS were conducted for
participants identifying as black or white to account for
ancestry heterogeneity statistically in a random-effects
meta-analysis. We also performed a sensitivity analyses
with European ancestry children only. Parents gave
informed consent for their children’s participation and local
ethics committees approved the study protocols. See Sup-
plementary Information 1 for full cohort descriptions.
DNA methylation and quality control (QC)
DNA methylation in cord blood was measured using the
Illumina Infinium HumanMethylation450K BeadChip
(Table S1). Methylation levels outside of the lower quar-
tile minus 3 × interquartile or upper quartile plus 3 ×
interquartile range were removed. Each cohort ran the
EWAS separately according to a pre-specified harmonized
analysis plan. The distribution of the regression estimates
and p values were examined for each cohort and pooled
results. Deviations from a normal distribution of regres-
sion estimates or a higher number of low p values than
expected by chance may be signs of residual confounding
or the result of a true poly-epigenetic signal. To help in
interpretation of the results, we used the BACON
method30. BACON analyzes the distribution of regression
coefficients and estimates an empirical null distribution.
Results can then be compared against the empirical null,
which already includes biases, rather than the theoretical
null. We excluded CpG probes, which were available in <4
cohorts; <1000 participants; and allosomal probes, due to
the complex interpretation of dosage compensation.
ADHD symptoms
ADHD symptoms were measured when children
were aged 4–15 years (depending on the cohort) with
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parent-rated instruments, specifically the Behavior
Assessment System for Children31, Child Behavior
Checklist (CBCL)32,33, Conners34 and the Development
and Well-Being Assessment (DAWBA)35 (Table S2). If a
cohort had measured ADHD symptoms repeatedly (three
cohorts), we used a mixed model (see “Statistical analy-
sis”). The repeated-measures design increased the preci-
sion of the ADHD severity estimate and sample size, since
missing data in an assessment can be handled with
maximum likelihood. Given the variety of instruments
used within and across cohorts, all ADHD scores were z-
score standardized to enable meta-analysis.
Statistical analysis
Cohorts with repeated ADHD assessment were ana-
lyzed using linear mixed models, with z-scores of ADHD
symptoms as the outcome and methylation (in betas,
ranging from 0 (unmethylated) to 1 (methylated)) as the
main predictor. Each CpG probe was analyzed separately
and pooled p values were adjusted for multiple correction
using Bonferroni adjustment. We used a random inter-
cept on the participant and batch level, to account for
clustering due to repeated measures and batch effects.
The following potential confounders were included as
fixed effects: maternal age, educational level, smoking
status (yes vs no during pregnancy), gestational age, sex,
and estimated white blood cell proportions (Bakulski
reference estimated with the Houseman method)36.
Mixed models were fitted using restricted maximum
likelihood. We used R37 with the lme438 package to esti-
mate the models. Cohorts with a single ADHD assess-
ment wave used a model without random effects or batch
level only.
Meta-analysis was performed using the Han and Eskin
random-effects model39. This model does not assume that
true effects are homogeneous between cohorts; however,
it does assume that null effects are homogeneous. This
modified version of the random effect model has com-
parable power to a fixed-effects analysis, while better
accounting for study heterogeneity, such as ancestry dif-
ferences, in simulation studies39,40. Genome-wide sig-
nificance was defined at the Bonferroni-adjustment
threshold of p < 1 × 10–7, suggestive significance at p < 1 ×
10–5, and nominal significance at p < 0.05.
Follow-up analyses
We performed several lookups of genome-wide sig-
nificant probes. We used the BECon database41 to check
the correlation between peripheral and brain methylation
levels in postmortem tissue. To test genetic influence, we
Table 1 Cohort characteristics.
Cohort Ancestry/ethnicity n Methylation age ADHD age Instrument (age) Standardized regression
coefficients
BACON estimates
33% 50% 66% λ Inflation Bias
Birth EWAS
ALSPAC European 714 0 8, 11, 14, 15 DAWBA −0.21 0.25 0.89 1.60 1.10 0.37
GENR European 1191 0 6, 8,10 CBCL (6,10), Conners (8) −0.48 0.01 0.53 1.51 1.20 0.05
INMA European 325 0 7, 9 Conners (7), CBCL (9) −1.37 −0.40 0.43 0.80 0.87 −0.19
NEST Black 55 0 5 BASC −3.50 −0.03 3.63 1.16 1.10 0.00
NEST White 56 0 5 BASC −2.54 −0.09 2.36 0.80 0.92 −0.01
PREDO European 136 0 5 Conners −1.55 −0.25 1.20 1.45 0.95 0.21
META – 2477 – – – −0.37 0.02 0.42 1.86 1.10 0.01
School-age EWAS
ALSPAC European 651 7 8 DAWBA −0.61 −0.10 0.54 1.09 1.00 −0.08
GENR European 395 10 10 CBCL −0.93 −0.00 0.98 1.00 0.97 −0.01
GLAKU European 215 12 12 CBCL −0.79 0.31 1.50 0.92 0.96 0.13
HELIX European 1034 8 8 CBCL −0.26 0.47 1.40 1.11 0.98 0.28
HELIX Pakistani 79 7 7 CBCL −1.66 1.86 5.48 0.98 0.96 0.26
Meta – 2374 – – – −0.24 0.14 0.62 0.96 0.92 0.14
n Number of participants, 33%, 50%, 66% quartiles of regression coefficient distribution, λ inflation of p values, Inflation inflation of p values due to suspected bias, Bias
trend toward negative/positive distribution of regression coefficients due to suspected bias.
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interrogated the genome-wide significant probes in
MeQTL42 and twin heritability databases43. We also
attempted to replicate genome-wide significant probes
reported in a previous EWAS from the ALSPAC study17.
For replication, we reran the meta-analysis without the
ALSPAC cohort. To quantify the variance explained by
genome-wide significant probes, we predicted ADHD
scores at age 8 years in Generation R by all meta-
analytically genome-wide significant probes. We applied
10-fold cross-validation with 100 repetitions to improve
generalizability and reduce bias from Generation R, which
was part of the discovery.
We examined whether any CpG sites associated with
ADHD symptoms are also associated with prenatal
maternal stress. As prenatal maternal stress is associated
with child psychopathology with mixed evidence of
affecting DNA methylation44,45, DNA methylation may be
a mediator of adverse prenatal stress effects. We oper-
ationalized prenatal maternal stress as in Rijlersdaam
et al.45 by using a factor score reflecting life, contextual,
personal stress, and interpersonal stress. One modifica-
tion to the previous definition is that maternal education
was not used in the computation of the factor score, as it
had been included as covariate in the EWAS model. We
first tested whether prenatal stress was associated with
ADHD symptoms with an analysis model equivalent to
the EWAS model, but instead of DNA methylation, the
prenatal risk score was the main predictor. We then tested
associations between prenatal stress as predictor and
DNA methylation as outcome. p Values were obtained
with the lmerTest package46. We estimated the prenatal
stress associations only in the Generation R cohort.
Pathway analysis
Pathway enrichment analysis were performed with the
missMethylpackage47 on suggestive probes (p < 1 × 10–5).
We used as references gene ontology, Kyoto Encyclopedia
of Genes and Genomes, and curated gene sets (http://
software.broadinstitute.org/gsea/msigdb/collections.jsp#C2)
from the Broad Institute Molecular signatures database48.
p Values were adjusted using the default procedures by the
number of CpGs associated with each gene49 and false
discovery rate.
To test enrichment for regulatory features (gene relative
position, CpG island relative position, and blood chro-
matin states), we applied χ2 tests. Enrichment tests were
performed for all CpGs, hypomethylated CpGs, and
hypermethylated CpGs separately. CpG annotation was
performed with the IlluminaHumanMethylation450kanno.
ilmn-12.hg19 R package50. Annotation to chromatin states
was from the Roadmap Epigenomics Project (https://egg2.
wustl.edu/roadmap/web_portal/). See Supplementary
Information 2 for full description.
School-age methylation EWAS
Participants
Nine cohorts (ALSPAC, GENR, HELIX51, and
GLAKU52) with a combined sample size of 2374 joined
the school-age methylation EWAS (Table 1 and Supple-
mentary Information 1). HELIX consists of six jointly
analyzed subcohorts51. All cohorts had participants of
European ancestry, except HELIX, which also included
participants with a Pakistani background living in the UK
and were treated as a separate cohort in the meta-analysis.
Again, we accounted for ancestry heterogeneity with a
random-effects meta-analysis and also present European
ancestry only results as sensitivity analysis. Fifty-three
percent of participants in the school-age EWAS were also
part of the birth EWAS.
DNA methylation and QC
DNA methylation was measured at ages 7–12 years in
peripheral whole blood. The Illumina Infinium Human-
Methylation450K BeadChip and Infinium Methylatio-
nEPIC Kit (GLAKU) were used to interrogate CpG probes.
QC steps were identical to the birth methylation EWAS.
ADHD symptoms
ADHD symptoms were measured at the same age as
DNA methylation (age 7–11 years) with the parent-rated
measures DAWBA and CBCL (Table S2). Only the
assessment closest to the DNA methylation assessment
age was analyzed.
Statistical analysis
The statistical model was similar to the model used in
the birth methylation EWAS without participant-level
random effect. However, cell counts were estimated with
the Houseman method using the Reinius reference53. We
also added assessment age as covariate. The meta-analysis
methods were identical to the birth methylation EWAS.
Follow-up analyses
We did not perform follow-up analyses due to low
signal. However, we attempted to replicate six probes
identified as suggestive in a previous case–control EWAS
in school age16.
Results
Birth cord blood methylation
EWAS quality check
Four out of the six cohorts showed larger number of low
p values than expected under the null, as indexed by high
λ (Table 1). BACON analysis suggested that the majority
of the inflation was due to a true signal, as indicated by
inflation values clearly <λ. To test the impact of sample
size on λ, we restricted the GENR sample randomly to 900
and 1100 participants, resulting in 812 and 991
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participants due to missing covariates. The lambdas were
0.96, 1.21, 1.51 for 812, 991, and 1191 participants. We
thus conclude that the overrepresentation of low p values
is mostly due to sufficient power to detect associations at
higher sample sizes.
The BACON analyses also indicated a trend toward
positive/negative regression coefficients in some of the
datasets, which might indicate confounding, e.g., by
population stratification. To test this, we added principal
components of ancestry in GENR and ALSPAC, but these
did not meaningfully change results.
We conducted the meta-analysis under the assumption
that any such biases will be corrected in the pooled
analysis, since they were not homogeneous across
cohorts. Indeed, the pooled estimates did not show a
trend toward positive or negative regression estimates
(Median=+0.02), only an overrepresentation of low
p values (λ= 1.86, Fig. 1). The BACON estimates for
inflation suggested that these are mostly due to a true
signal (Inflation= 1.1).
Single probe analysis
After QC, 472,817 CpG sites remained for the meta-
analysis. Results of the cord blood EWAS are shown in
Fig. 2. Nine CpG sites showed genome-wide significance
(p < 1 × 10–7, Table 2). ADHD symptoms were between
0.16 SD (SE= 0.03) and 0.44 SD (SE= 0.12) higher with
10% lower methylation at these probes. Eight probes out
of nine that were available in the BECon database41 are
typically methylated in both whole blood and the brain
(Figs. 3, S1, and S2). A lookup in the BECon database
revealed that the CpG site cg01271805 in the promoter
region of gene ERC2 shows variable methylation in three
brain regions (BA10, BA20, BA7). Importantly, methyla-
tion levels in the brain are moderately correlated with
whole-blood methylation (ρ= 0.33–0.46; Fig. 3), sug-
gesting that peripheral cg01271805 methylation levels are
a useful marker for brain methylation levels. The other
seven genome-wide significant probes showed less con-
sistent correlations between blood and brain tissues and
associated genes had less specificity for expression in the
brain, based on GTEx54 data. No single-nucleotide poly-
morphism (SNP) was associated with our nine top CpG
probes when accounting for linkage disequilibrium
according to the MeQTL database42. Furthermore, all
nine probes had a twin heritability <20% in a previous
study (Table S3)43. In Generation R, the joint explained
variance of ADHD scores at age 8 years by the genome-
wide significant probes was 2.0.% (R2 from 10-fold repe-
ated cross-validation). Full EWAS results can be found in
Supplementary Data. After adjusting for inflation and bias
with BACON, only one CpG remained statistically sig-
nificant (cg25520701, CREB5, β=−3.54, SE= 0.66, p=
9.59 × 10–8). It should be noted that the BACON adjusted
p values rely on statistics from the traditional random
effects model. With the traditional model, only
cg25520701, cg09762907, and cg22997238 remained
genome-wide significant. Thus the difference in p value is
not solely the result of adjustment for the inflation but
also the use of more conservative tests. When restricting
analyses to participants with European ancestry, top hits
remained unchanged but one additional CpG site became
genome-wide significant: cg10025904 in gene LRRC8B
(Table S4).
Prenatal stress was associated with ADHD symptoms in
childhood. One SD higher prenatal stress was associated
with 0.2 SD higher ADHD symptoms (SE= 0.03, p= 2E
−13, n= 1121). However, prenatal stress was not asso-
ciated with any of the genome-wide significant sites
(Table S5).
Fig. 1 Quantile–quantile plot of observed −log10 p values in the cord blood and school-age EWAS vs expected −log10 p values under
assumption of chance findings only. The diagonal line represents the distribution of the expected p values under the null. Points above the
diagonal indicate p values that are lower than expected.
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Pathway analysis
Two-hundred forty-nine probes showed suggestive (p <
1 × 10–5) associations and were annotated to 182 unique
genes. In gene-based analyses, no pathway survived mul-
tiple testing correction.
The 248 suggestive CpGs were enriched in intergenic
regions. Of these, hypomethylated CpGs were enriched
for 3’-untranslated regions and depleted for TSS200 and
first exon regions, open sea, north shelf and south shelf
regions, south shore, and islands. Regarding chromatin
Fig. 2 Manhattan plot of −log10 p values vs CpG position (basepair and chromosome). Red line indicates genome-wide significant (p < 1 × 10
–7)
and blue line suggestive threshold (p < 1 × 10–5).
Table 2 EWAS results.
CpG Gene Chr Position Birth methylation School-age methylation
nstudies n B SE p nstudies n B SE p
cg25520701 CREB5 7 28,800,657 6 2450 −3.53 0.60 4.95E−09 5 2279 −0.13 1.09 0.94
cg24838839 Intergenic 5 61,031,569 6 2468 −4.15 1.79 3.95E−08 5 2287 1.52 1.38 0.33
cg22997238 Intergenic 7 36,014,218 6 2465 −1.63 0.30 8.81E−08 5 2291 −0.06 0.47 0.94
cg21600027 Intergenic 4 124,443,502 6 2464 −3.04 0.81 2.64E−08 5 2281 0.98 0.89 0.33
cg17876201 ZBTB38 3 141,139,991 6 2457 −4.41 1.20 7.58E−09 4 2066 0.56 1.32 0.73
cg11251614 PPIL1 6 36,839,846 6 2451 −3.43 0.68 3.89E−08 5 2276 0.77 1.52 0.68
cg09762907 TRERF1 6 42,290,256 6 2460 −2.11 0.39 8.76E−08 5 2284 −0.55 0.64 0.46
cg09158638 Intergenic 16 62,309,996 6 2470 −2.55 1.40 1.89E−08 5 2270 −0.33 1.04 0.80
cg01271805 ERC2 3 55,694,954 6 2469 −2.86 1.71 5.24E−08 5 2289 0.28 0.73 0.76
Chr chromosome, nstudies number of studies, n number of participants, B regression coefficient, SE standard error.
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states, hypomethylated probes showed an enrichment for
transcription (Tx and TxWk), quiescent positions, and
depletion for transcription start site positions (TSSA,
TxFlnk, TxFlnk), bivalent (EnhBiv), and repressor
(ReprPC) positions. Hypermethylated probes showed the
opposite enrichment/depletion patterns. See Supplemen-
tary Information 2 for full results.
Replication of previous EWAS
We attempted to replicate findings for 13 CpGs, at
which DNA methylation at birth was associated with
ADHD trajectories17. However, no probe survived mul-
tiple testing correction (Table S6).
School-age methylation
EWAS quality checks
The regression coefficient distribution showed no signs
of errors, but three out of the five cohorts showed a trend
toward positive associations in separate analyses (Table 1).
The lambda was below 1.11 for all cohorts. BACON
suggested no inflation of the test statistics due to con-
founding or other biases, though the trend toward positive
associations remained. The pooled results showed a low
lambda (λ= 0.96), no inflation (BACON inflation esti-
mate= 0.92), but a slight overrepresentation of positive
associations (BACON bias estimate= 0.14).
Single probe meta-analysis
We associated DNA methylation at school age in whole
blood at 466,574 CpG sites with ADHD symptoms at the
same age. No CpG reached genome-wide significance (all
p > 4.96E−06, Fig. 2). Furthermore, none of the loci at
which DNA methylation at birth was significantly asso-
ciated with ADHD symptoms showed a cross-sectional
association at school age (p > 0.33, Table 2). Restricting
analyses to children with European ancestry did not
change these results.
Replication of previous EWAS
We attempted to replicate the six most suggestive
EWAS CpGs of a previous case–control study16. While all
but one showed a consistent direction, none of the CpGs
were statistically significant (Table S7).
Stability of methylation association across age
The associations between methylation at birth with
ADHD symptoms and methylation at school age with
ADHD symptoms were largely consistent for nominally
significant probes. The regression estimates from CpG
sites, with nominally significant associations at birth (p <
0.05, n= 73,057) correlated with the regression estimates
of the school-age EWAS (ρ= 0.45). When restricting the
school-age methylation EWAS to those cohorts, which
were not featured in the birth methylation EWAS (thus
excluding overlaps), the correlation remained (ρ= 0.30).
Vice versa, when filtering for probes that were nominally
significant at school age, 23,770 probes remained of which
4075 overlapped with nominally significant probes at
birth. The correlation for this set was very similar, ρ=
0.47 among all cohorts and ρ= 0.35 between independent
cohorts.
Discussion
In this population-based study, we performed the first
epigenome-wide meta-analysis of ADHD symptoms in
childhood, using two DNA methylation assessments
(birth and school age), as well as repeated measures of
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Fig. 3 Lookup of brain–blood correlations and variability of genome-wide significant CpG sites in the BECon database. Columns 1-4
indicate the locations of the CpG sites. Columns 5-8 show the variability of DNA methylation in three brain regions and blood, with higher values
indicating higher variability. Columns 9-11 contain the correlations between brain and blood DNA methylation levels. Columns 12-13 state how
much DNA methylation is influenced by cell composition, with higher values indicating higher effect.
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school age, was associated with later development of
ADHD symptoms with genome-wide significance at nine
loci. Interestingly, the identified probes showed a pattern
of a high average rate of methylation in cord blood, while
lower levels of methylation were associated with more
ADHD symptoms in childhood. DNA methylation in cord
blood reflects the effects of genetics and the intrauterine
environment. The results suggest that cord blood DNA
methylation is a marker for some of the ADHD risk fac-
tors before birth or functions as a potential mediator of
these risk factors. While not impossible, reverse causality
at this age is unlikely to explain our results, as ADHD only
manifests at later stages of development.
We analyzed DNA methylation in cord and peripheral
blood, which may not correspond to the methylation
status in the brain. While DNA methylation in the per-
iphery may affect behavior via various pathways (e.g., by
affecting systemic inflammation), DNA methylation in the
brain arguably has the strongest a priori likelihood of
representing causal mechanisms. Seven out of eight sig-
nificant probes did not show consistent correlation
between methylation status in whole blood and post-
mortem brain tissue in a previous study, i.e., DNA
methylation levels in blood may not represent brain levels
and thus associations with ADHD may be different41.
However, methylation levels of cg01271805 in whole
blood are associated with methylation levels in various
brain regions. Importantly, this probe lies in the promoter
region of the gene ERC2, which is highly expressed in
brain tissue. ERC2 regulates calcium-dependent neuro-
transmitter release in the axonal terminal55. Specifically,
ERC2 is suspected to increase the sensitivity of voltage-
dependent calcium channels to hyperpolarization, result-
ing in higher neurotransmitter release. SNPs in the ERC2
locus have been suggested to distinguish schizophrenia
and bipolar disorder patients56 and to impact cognitive
functioning57. ERC2 is especially expressed in Brodmann
area 9 of the frontal cortex54. Previous imaging studies
have demonstrated differential activation in this area
when children with or without ADHD performed various
cognitive tasks58,59. The correlation with brain methyla-
tion, the location in a promoter, and gene expression in
the brain make cg01271805 a plausible candidate locus,
where reduced methylation may be mechanistically
involved in ADHD development. We hypothesize that
lower methylation levels at cg01271805 increases the
expression of ERC2, which in turn increases neuro-
transmitter release, with an adverse impact on the
development of ADHD symptoms. Another gene with a
genome-wide significant probe and high relevance for
neural functioning is CREB5 (cg25520701). CREB5 is
expressed in the fetal brain and the prefrontal cortex and
has been previously related to neurite outgrowth. More-
over, SNPs in this gene were associated with ADHD in
two recent GWAS60,61. Thus it is plausible that differ-
ences in DNA methylation at this locus may modify
ADHD risk during development. To the best of our
knowledge, none of the top CpG sites have been asso-
ciated with psychopathology before.
While the birth methylation EWAS identified several
loci, associating school-age methylation with concurrent
ADHD symptoms revealed no genome-wide significant
associations. Furthermore, the overall association signal
was lower, despite similar sample sizes. None of the
probes, which were significantly associated at birth,
showed any association when measured at school age.
Given that sample sizes were comparable, this difference
must come from changes in the epigenome or study
heterogeneity, rather than differences in statistical power.
In terms of instrument heterogeneity, the school-age
EWAS was more homogeneous, almost exclusively using
CBCL. Additionally, as both EWAS feature a mix of
several cohorts selected based on the same criteria and
around half of the participants were represented at both
timepoints, study heterogeneity appears to be an unlikely
explanation. The stronger signal in the birth EWAS may
be considered surprising given that typically two measures
are more strongly associated if measured in closer tem-
poral proximity. However, in line with our results Walton
et al. also observed in a previous EWAS17 that birth
methylation may be a better predictor of later ADHD
symptoms than childhood methylation, possibly reflecting
sensitive periods. Whether DNA methylation in cord
blood has stronger causal effects or is a better marker for
early life factors cannot be concluded from the present
study. Alternatively, tissue differences between cord blood
and whole blood may account for the differences in
association pattern. Finally, it is possible that interventions
in childhood and other environmental influences reduced
the initial epigenetic differences at birth between children
with higher and lower ADHD symptoms. Yet, we observed
consistency in the associations of methylation at both
timepoints with ADHD symptoms. The regression esti-
mates of both EWAS correlated on a genome-wide level.
Strengths of this study include the large sample size,
repeated outcome measures, extensive control for
potential confounders, and the use of DNA methylation at
two different timepoints, enabling us to characterize both
prospective and cross-sectional associations with ADHD
symptoms. However, several limitations need to be dis-
cussed as well. A causal interpretation of our findings is
challenged by the possibility of residual confounding and
reverse causality. DNA methylation might be a marker for
untested adverse environmental factors that could affect
ADHD via independent pathways. In addition, children
with higher ADHD symptoms may evoke a particular
environment, which might shape the epigenome. Fur-
thermore, we had limited ability to infer from our data
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DNA methylation in the brain during birth, as the BECon
database is based on a small sample size, features a limited
selection of brain areas, and DNA methylation is mea-
sured postmortem. As is typical for (epi-)genetic studies,
the effect size of individual top probes was rather small in
our study: the joint effect of the genome-wide probes was
estimated at 2%. However, the strong genome-wide epi-
genetic signal suggests a potential for the development of
epigenetic scores based on birth methylation, which could
lead to early prevention efforts before ADHD symptoms
arise. Future studies with larger sample sizes are therefore
necessary to detect further methylation sites.
In summary, we identified nine CpG sites for which
lower methylation status at birth is associated with later
development of ADHD symptoms. The results suggest
that DNA methylation in ERC2 and CREB5 may exert an
influence on ADHD symptoms, potentially via modifica-
tion of neurotransmitter functioning or neurite outgrowth.
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